{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T05:25:19Z","timestamp":1794979519116,"version":"4.9.1"},"reference-count":86,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,9]]},"abstract":"<jats:p>Coronary artery disease (CAD) remains a leading cause of global morbidity and mortality, necessitating continuous refinement in the management of dyslipidemia, one of its major risk factors, to mitigate cardiovascular risks. Previous studies have proven the critical role of immediate and robust low-density lipoprotein cholesterol (LDL-C) reduction in the aftermath of acute coronary syndrome (ACS). Emphasizing the evidence supporting this approach, we delve into the impact of early intervention on cardiovascular outcomes and propose optimal strategies for achieving rapid LDL-C lowering, while also providing the rationale for early proprotein convertase subtilisin\/kexin 9 inhibitor use after an ACS. Given the importance of the residual lipidemic risk, we present an overview of emerging therapeutic avenues poised to reshape dyslipidemia management, such as bempedoic acid, lipoprotein(a) inhibition, ApoC3 modulation, and angiopoietin-like protein 3 targeting. This comprehensive review amalgamates current evidence with future prospects, offering a holistic perspective on the management of dyslipidemia in CAD. By exploring both the urgency for immediate post-ACS LDL-C reduction and the exciting advancements on the horizon, this article provides a roadmap for clinicians navigating the intricate landscape of lipid-lowering therapies in CAD.<\/jats:p>","DOI":"10.1097\/mca.0000000000001375","type":"journal-article","created":{"date-parts":[[2024,4,29]],"date-time":"2024-04-29T06:00:08Z","timestamp":1714370408000},"page":"516-524","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":18,"title":["Management of dyslipidemia in coronary artery disease: the present and the future"],"prefix":"10.1097","volume":"35","author":[{"given":"Kyriakos","family":"Dimitriadis","sequence":"first","affiliation":[{"name":"First Department of Cardiology, School of Medicine, National and Kapodistrian University of Athens"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Panagiotis","family":"Theofilis","sequence":"additional","affiliation":[{"name":"First Department of Cardiology, School of Medicine, National and Kapodistrian University of Athens"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Panagiotis","family":"Iliakis","sequence":"additional","affiliation":[{"name":"First Department of Cardiology, School of Medicine, National and Kapodistrian University of Athens"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikolaos","family":"Pyrpyris","sequence":"additional","affiliation":[{"name":"First Department of Cardiology, School of Medicine, National and Kapodistrian University of Athens"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eirini","family":"Dri","sequence":"additional","affiliation":[{"name":"First Department of Cardiology, School of Medicine, National and Kapodistrian University of Athens"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Athanasios","family":"Sakalidis","sequence":"additional","affiliation":[{"name":"First Department of Cardiology, School of Medicine, National and Kapodistrian University of Athens"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stergios","family":"Soulaidopoulos","sequence":"additional","affiliation":[{"name":"First Department of Cardiology, School of Medicine, National and Kapodistrian University of Athens"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Panagiotis","family":"Tsioufis","sequence":"additional","affiliation":[{"name":"First Department of Cardiology, School of Medicine, National and Kapodistrian University of Athens"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christos","family":"Fragkoulis","sequence":"additional","affiliation":[{"name":"First Department of Cardiology, School of Medicine, National and Kapodistrian University of Athens"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina","family":"Chrysohoou","sequence":"additional","affiliation":[{"name":"First Department of Cardiology, School of Medicine, National and Kapodistrian University of Athens"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dimitrios","family":"Tsiachris","sequence":"additional","affiliation":[{"name":"First Department of Cardiology, School of Medicine, National and Kapodistrian University of Athens"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Konstantinos","family":"Tsioufis","sequence":"additional","affiliation":[{"name":"First Department of Cardiology, School of Medicine, National and Kapodistrian University of Athens"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2024,4,29]]},"reference":[{"key":"R1-20250729","doi-asserted-by":"crossref","first-page":"2361","DOI":"10.1016\/j.jacc.2022.11.005","article-title":"The global burden of cardiovascular diseases and risk: a compass for future health.","volume":"80","author":"Vaduganathan","year":"2022","journal-title":"J Am Coll Cardiol"},{"key":"R2-20250729","doi-asserted-by":"crossref","first-page":"2459","DOI":"10.1093\/eurheartj\/ehx144","article-title":"Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemio-logic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel.","volume":"38","author":"Ference","year":"2017","journal-title":"Eur Heart J"},{"key":"R3-20250729","doi-asserted-by":"crossref","first-page":"3720","DOI":"10.1093\/eurheartj\/ehad191","article-title":"2023 ESC Guidelines for the management of acute coronary syndromes.","volume":"44","author":"Byrne","year":"2023","journal-title":"Eur Heart J"},{"key":"R4-20250729","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1056\/NEJMoa040583","article-title":"Intensive versus moderate lipid lowering with statins after acute coronary syndromes.","volume":"350","author":"Cannon","year":"2004","journal-title":"N Engl J Med"},{"key":"R5-20250729","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1056\/NEJMoa050461","article-title":"Intensive lipid lowering with atorvastatin in patients with stable coronary disease.","volume":"352","author":"LaRosa","year":"2005","journal-title":"N Engl J Med"},{"key":"R6-20250729","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.1056\/NEJMoa1410489","article-title":"Ezetimibe added to statin therapy after acute coronary syndromes.","volume":"372","author":"Cannon","year":"2015","journal-title":"N Engl J Med"},{"key":"R7-20250729","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1016\/S0140-6736(22)00916-3","article-title":"Long-term efficacy and safety of moderate-intensity statin with ezetimibe combination therapy versus high-intensity statin monotherapy in patients with atherosclerotic cardiovascular disease (RACING): a randomised, open-label, non-inferiority trial.","volume":"400","author":"Kim","year":"2022","journal-title":"Lancet"},{"key":"R8-20250729","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.jacc.2023.05.042","article-title":"Combination lipid-lowering therapy in patients undergoing percutaneous coronary intervention.","volume":"82","author":"Lee","year":"2023","journal-title":"J Am Coll Cardiol"},{"key":"R9-20250729","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1001\/jama.2016.13985","article-title":"Associ-ation between lowering LDL-C and cardiovascular risk reduction among different therapeutic interventions: a systematic review and meta-analysis.","volume":"316","author":"Silverman","year":"2016","journal-title":"JAMA"},{"key":"R10-20250729","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1016\/j.jacc.2005.05.085","article-title":"Pleiotropic effects of statins: benefit beyond cholesterol reduction? A meta-regression analysis.","volume":"46","author":"Robinson","year":"2005","journal-title":"J Am Coll Cardiol"},{"key":"R11-20250729","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.atherosclerosis.2019.08.014","article-title":"2019 ESC\/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk.","volume":"290","year":"2019","journal-title":"Atherosclerosis"},{"key":"R12-20250729","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1056\/NEJMoa1615664","article-title":"Evolocumab and clinical outcomes in patients with cardiovascular disease.","volume":"376","author":"Sabatine","year":"2017","journal-title":"N Engl J Med"},{"key":"R13-20250729","doi-asserted-by":"crossref","first-page":"1962","DOI":"10.1016\/S0140-6736(17)32290-0","article-title":"Clinical efficacy and safety of achieving very low LDL-cholesterol concentrations with the PCSK9 inhibitor evolocumab: a prespecified secondary analysis of the FOURIER trial.","volume":"390","author":"Giugliano","year":"2017","journal-title":"Lancet"},{"key":"R14-20250729","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1056\/NEJMoa1801174","article-title":"Alirocumab and cardiovascular outcomes after acute coronary syndrome.","volume":"379","author":"Schwartz","year":"2018","journal-title":"N Engl J Med"},{"key":"R15-20250729","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.1016\/j.amjcard.2014.02.034","article-title":"Meta-analysis of time-related benefits of statin therapy in patients with acute coronary syndrome undergoing percutaneous coronary intervention.","volume":"113","author":"Navarese","year":"2014","journal-title":"Am J Cardiol"},{"key":"R16-20250729","doi-asserted-by":"crossref","first-page":"e888","DOI":"10.4244\/EIJ-D-22-00735","article-title":"Effects of routine early treatment with PCSK9 inhibitors in patients undergoing primary percutaneous coronary intervention for ST-segment elevation myocardial infarction: a randomised, double-blind, sham-controlled trial.","volume":"18","author":"Mehta","year":"2022","journal-title":"EuroIntervention"},{"key":"R17-20250729","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1161\/CIRCULATIONAHA.120.046320","article-title":"Effect of evolocumab on atherogenic lipoproteins during the peri- and early postinfarction period: a place-bo-controlled, randomized trial.","volume":"142","author":"Leucker","year":"2020","journal-title":"Circulation"},{"key":"R18-20250729","doi-asserted-by":"crossref","first-page":"2452","DOI":"10.1016\/j.jacc.2019.08.010","article-title":"Evolocumab for early reduction of LDL cholesterol levels in patients with acute coronary syndromes (EVOPACS).","volume":"74","author":"Koskinas","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"R19-20250729","doi-asserted-by":"crossref","first-page":"2025","DOI":"10.1253\/circj.CJ-19-0412","article-title":"Effect of alirocumab on coronary atheroma volume in Japanese patients with acute coronary syndrome - the ODYSSEY J-IVUS trial.","volume":"83","author":"Ako","year":"2019","journal-title":"Circ J"},{"key":"R20-20250729","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1016\/j.jcmg.2022.03.002","article-title":"Effect of evolocumab on coronary plaque phenotype and burden in statin-treated patients following myocardial infarction.","volume":"15","author":"Nicholls","year":"2022","journal-title":"JACC Cardiovasc Imaging"},{"key":"R21-20250729","doi-asserted-by":"crossref","first-page":"2012","DOI":"10.1016\/j.jacc.2018.06.078","article-title":"Effect of evolocumab on coronary plaque composition.","volume":"72","author":"Nicholls","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"R22-20250729","doi-asserted-by":"crossref","first-page":"2373","DOI":"10.1001\/jama.2016.16951","article-title":"Effect of evolocumab on progression of coronary disease in statin-treated patients: the GLAGOV randomized clinical trial.","volume":"316","author":"Nicholls","year":"2016","journal-title":"JAMA"},{"key":"R23-20250729","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1093\/ehjcvp\/pvad089","article-title":"The potential future role of extensive lipid lowering in ACS patients with the use of PCSK9 inhibitors: early bird catches the worm.","volume":"10","author":"Dimitriadis","year":"2023","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"R24-20250729","doi-asserted-by":"crossref","first-page":"13457","DOI":"10.1038\/ncomms13457","article-title":"Liver-specific ATP-citrate lyase inhibition by bempedoic acid decreases LDL-C and attenuates atherosclerosis.","volume":"7","author":"Pinkosky","year":"2016","journal-title":"Nat Commun"},{"key":"R25-20250729","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1161\/ATVBAHA.117.310676","article-title":"Bempedoic acid lowers low-density lipoprotein cholesterol and attenuates atherosclerosis in low-density lip-oprotein receptor-deficient (LDLR(\u00b1) and LDLR(\/)) Yucatan miniature pigs.","volume":"38","author":"Burke","year":"2018","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"R26-20250729","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1161\/ATVBAHA.116.308963","article-title":"Prevention of diet-induced metabolic dysregulation, inflammation, and atherosclerosis in LDLR(\/) mice by treat-ment with the ATP-citrate lyase inhibitor bempedoic acid.","volume":"37","author":"Samsoondar","year":"2017","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"R27-20250729","doi-asserted-by":"crossref","first-page":"109392","DOI":"10.1016\/j.intimp.2022.109392","article-title":"Bempedoic acid, an ATP citrate lyase inhibitor, reduces intimal hyperplasia via activation of AMPKalpha signaling pathway.","volume":"113","author":"Liu","year":"2022","journal-title":"Int Immunopharmacol"},{"key":"R28-20250729","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.atherosclerosis.2023.03.020","article-title":"Bempedoic acid lowers high-sensitivity C-reactive protein and low-density lipoprotein cholesterol: analysis of pooled data from four phase 3 clinical trials.","volume":"373","author":"Stroes","year":"2023","journal-title":"Atherosclerosis"},{"key":"R29-20250729","doi-asserted-by":"crossref","first-page":"1780","DOI":"10.1001\/jama.2019.16585","article-title":"Effect of bempedoic acid vs placebo added to maximally tolerated statins on low-density lipoprotein cholesterol in patients at high risk for cardiovascular disease: the CLEAR wisdom randomized clinical trial.","volume":"322","author":"Goldberg","year":"2019","journal-title":"JAMA"},{"key":"R30-20250729","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1056\/NEJMoa1803917","article-title":"Safety and efficacy of bempedoic acid to reduce LDL cholesterol.","volume":"380","author":"Ray","year":"2019","journal-title":"N Engl J Med"},{"key":"R31-20250729","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.atherosclerosis.2018.06.002","article-title":"Efficacy and safety of bempedoic acid added to ezetimibe in statin-intolerant patients with hypercholesterolemia: a randomized, placebo-controlled study.","volume":"277","author":"Ballantyne","year":"2018","journal-title":"Atherosclerosis"},{"key":"R32-20250729","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1056\/NEJMoa2215024","article-title":"Bempedoic acid and cardiovascular outcomes in statin-intolerant patients.","volume":"388","author":"Nissen","year":"2023","journal-title":"N Engl J Med"},{"key":"R33-20250729","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1001\/jama.2023.9696","article-title":"Bempedoic acid for primary prevention of cardiovascular events in statin-intolerant patients.","volume":"330","author":"Nissen","year":"2023","journal-title":"JAMA"},{"key":"R34-20250729","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/S2213-8587(23)00316-9","article-title":"Ef-ficacy and safety of bempedoic acid among patients with and without diabetes: prespecified analysis of the CLEAR outcomes randomised trial.","volume":"12","author":"Ray","year":"2024","journal-title":"Lancet Diabetes Endocrinol"},{"key":"R35-20250729","first-page":"69","article-title":"Safety of bempedoic acid in patients at high cardiovascular risk and with statin intolerance.","volume":"18","author":"Bays","year":"2023","journal-title":"J Clin Lipidol"},{"key":"R36-20250729","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1093\/ehjcvp\/pvad052","article-title":"Cardiovascular events in patients treated with bempedoic acid vs. placebo: systematic review and meta-analysis.","volume":"9","author":"Mutschlechner","year":"2023","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"R37-20250729","doi-asserted-by":"crossref","first-page":"969","DOI":"10.3390\/molecules28030969","article-title":"Lipoprotein(a) in atherosclerotic diseases: from pathophysiology to diagnosis and treatment.","volume":"28","author":"Lampsas","year":"2023","journal-title":"Molecules"},{"key":"R38-20250729","doi-asserted-by":"crossref","first-page":"117405","DOI":"10.1016\/j.atherosclerosis.2023.117405","article-title":"The association of lipoprotein (a) with coronary artery calcification: a systematic review and meta-analysis.","volume":"388","author":"Qiu","year":"2023","journal-title":"Atherosclerosis"},{"key":"R39-20250729","doi-asserted-by":"crossref","first-page":"1991","DOI":"10.1093\/eurjpc\/zwaa063","article-title":"Lipoprotein(a) and cardiovascular disease: prediction, attributable risk fraction, and estimating benefits from novel interventions.","volume":"28","author":"Welsh","year":"2022","journal-title":"Eur J Prev Cardiol"},{"key":"R40-20250729","doi-asserted-by":"crossref","first-page":"e81","DOI":"10.1093\/eurjpc\/zwad164","article-title":"Effect of lipoprotein(a) levels on coronary lesion complexity in patients with acute myocardial infarction: data from the French RICO survey.","volume":"30","author":"Kouame","year":"2023","journal-title":"Eur J Prev Cardiol"},{"key":"R41-20250729","doi-asserted-by":"crossref","first-page":"oead077","DOI":"10.1093\/ehjopen\/oead077","article-title":"Cardiovascular outcomes in patients with coronary artery disease and elevated lipoprotein(a): implications for the OCEAN(a)-outcomes trial population.","volume":"3","author":"Shiyovich","year":"2023","journal-title":"Eur Heart J Open"},{"key":"R42-20250729","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1186\/s12959-022-00424-9","article-title":"Lipoprotein(a) predicts recurrent cardiovascular events in patients with prior cardiovascular events post-PCI: five-year findings from a large single center cohort study.","volume":"20","author":"Xu","year":"2022","journal-title":"Thromb J"},{"key":"R43-20250729","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1016\/j.jacl.2023.05.094","article-title":"Association between lipoprotein(a) and long-term outcomes after percutaneous coronary intervention for lesions with in-stent restenosis.","volume":"17","author":"Zhang","year":"2023","journal-title":"J Clin Lipidol"},{"key":"R44-20250729","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1016\/j.jcin.2021.07.042","article-title":"Association of lipoprotein(a) with recurrent ischemic events following percutaneous coronary intervention.","volume":"14","author":"Yoon","year":"2021","journal-title":"JACC Cardiovasc Interv"},{"key":"R45-20250729","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1186\/s12944-019-1092-6","article-title":"Prognostic value of lipoprotein (a) level in patients with coronary artery disease: a meta-analysis.","volume":"18","author":"Wang","year":"2019","journal-title":"Lipids Health Dis"},{"key":"R46-20250729","doi-asserted-by":"crossref","first-page":"2239","DOI":"10.1016\/S0140-6736(16)31009-1","article-title":"Antisense oligonucleotides targeting apolipoprotein(a) in people with raised lipoprotein(a): two randomised, double-blind, placebo-controlled, dose-ranging trials.","volume":"388","author":"Viney","year":"2016","journal-title":"Lancet"},{"key":"R47-20250729","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.jacl.2022.12.001","article-title":"Efficacy and safety of pelacarsen in lowering Lp(a) in healthy Japanese subjects.","volume":"17","author":"Karwatowska-Prokopczuk","year":"2023","journal-title":"J Clin Lipidol"},{"key":"R48-20250729","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.atherosclerosis.2021.03.036","article-title":"Prev-alence and influence of LPA gene variants and isoform size on the Lp(a)-lowering effect of pelacarsen.","volume":"324","author":"Karwatowska-Prokopczuk","year":"2021","journal-title":"Atherosclerosis"},{"key":"R49-20250729","doi-asserted-by":"crossref","first-page":"2262","DOI":"10.1093\/eurheartj\/ehaa171","article-title":"Potent lipoprotein(a) lowering following apolipoprotein(a) antisense treatment reduces the pro-inflammatory activation of circulating monocytes in patients with elevated lipoprotein(a).","volume":"41","author":"Stiekema","year":"2020","journal-title":"Eur Heart J"},{"key":"R50-20250729","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1056\/NEJMoa1905239","article-title":"Lipoprotein(a) reduction in persons with cardiovascular disease.","volume":"382","author":"Tsimikas","year":"2020","journal-title":"N Engl J Med"},{"key":"R51-20250729","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1038\/s41591-021-01634-w","article-title":"Preclinical development and phase 1 trial of a novel siRNA targeting lipoprotein(a).","volume":"28","author":"Koren","year":"2022","journal-title":"Nat Med"},{"key":"R52-20250729","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1016\/j.clinthera.2022.07.008","article-title":"Pharmacokinetics, phar-macodynamics, and tolerability of olpasiran in healthy Japanese and non-Japanese participants: results from a phase I, sin-gle-dose, open-label study.","volume":"44","author":"Sohn","year":"2022","journal-title":"Clin Ther"},{"key":"R53-20250729","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1056\/NEJMoa2211023","article-title":"Small interfering RNA to reduce lipoprotein(a) in cardiovascular disease.","volume":"387","author":"O\u2019Donoghue","year":"2022","journal-title":"N Engl J Med"},{"key":"R54-20250729","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/j.atherosclerosis.2022.03.029","article-title":"Pre-clinical assessment of SLN360, a novel siRNA targeting LPA, developed to address elevated lipo-protein (a) in cardiovascular disease.","volume":"349","author":"Rider","year":"2022","journal-title":"Atherosclerosis"},{"key":"R55-20250729","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1093\/toxsci\/kfac067","article-title":"Preclinical toxico-logical assessment of a novel siRNA, SLN360, targeting elevated lipoprotein (a) in cardiovascular disease.","volume":"189","author":"Rider","year":"2022","journal-title":"Toxicol Sci"},{"key":"R56-20250729","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.1001\/jama.2022.5050","article-title":"Single ascending dose study of a short interfering RNA targeting lipoprotein(a) production in individuals with ele-vated plasma lipoprotein(a) levels.","volume":"327","author":"Nissen","year":"2022","journal-title":"JAMA"},{"key":"R57-20250729","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1001\/jama.2023.21835","article-title":"Lepodisiran, an extended-duration short interfering RNA targeting lipoprotein(a): a randomized dose-ascending clinical trial.","volume":"330","author":"Nissen","year":"2023","journal-title":"JAMA"},{"key":"R58-20250729","doi-asserted-by":"crossref","first-page":"2095","DOI":"10.1161\/ATVBAHA.120.314368","article-title":"Apolipo-protein CIII deficiency protects against atherosclerosis in knockout rabbits.","volume":"40","author":"Yan","year":"2020","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"R59-20250729","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.atherosclerosis.2018.11.006","article-title":"Plasma levels of apolipoproteins C-III, A-IV, and E are independently associated with stable atherosclerotic cardiovascular disease.","volume":"281","author":"Dittrich","year":"2019","journal-title":"Atherosclerosis"},{"key":"R60-20250729","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1186\/s12944-020-01293-9","article-title":"Apolipoprotein CIII predicts cardiovascular events in patients with coronary artery disease: a prospective observational study.","volume":"19","author":"Katzmann","year":"2020","journal-title":"Lipids Health Dis"},{"key":"R61-20250729","doi-asserted-by":"crossref","first-page":"e53","DOI":"10.1093\/eurjpc\/zwaa152","article-title":"Triglyceride-rich lipo-proteins, apolipoprotein C-III, angiopoietin-like protein 3, and cardiovascular events in older adults: Atherosclerosis Risk in Communities (ARIC) study.","volume":"29","author":"Hussain","year":"2022","journal-title":"Eur J Prev Cardiol"},{"key":"R62-20250729","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1161\/ATVBAHA.117.309007","article-title":"Apolipoprotein C-III levels and incident coronary artery disease risk: the EPIC-Norfolk prospective population study.","volume":"37","author":"van Capelleveen","year":"2017","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"R63-20250729","doi-asserted-by":"crossref","first-page":"e052388","DOI":"10.1136\/bmjopen-2021-052388","article-title":"Association of apolipoprotein Cs with new-onset type 2 diabetes mellitus: findings from the Chinese multi-provincial cohort study.","volume":"11","author":"Li","year":"2021","journal-title":"BMJ open"},{"key":"R64-20250729","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.atherosclerosis.2018.05.014","article-title":"Apolipoprotein CIII and N-terminal prohormone b-type natriuretic peptide as independent predictors for cardiovascular disease in type 2 diabetes.","volume":"274","author":"Colombo","year":"2018","journal-title":"Atherosclerosis"},{"key":"R65-20250729","doi-asserted-by":"crossref","first-page":"14554","DOI":"10.1038\/s41598-022-18914-1","article-title":"Apolipoprotein C3 and necrotic core volume are correlated but also associated with future cardiovascular events.","volume":"12","author":"Ohwada","year":"2022","journal-title":"Sci Rep"},{"key":"R66-20250729","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1056\/NEJMoa1400283","article-title":"Antisense inhibition of apolipoprotein C-III in patients with hypertriglyceridemia.","volume":"373","author":"Gaudet","year":"2015","journal-title":"N Engl J Med"},{"key":"R67-20250729","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.atherosclerosis.2023.05.008","article-title":"Long-term effects of volanesorsen on triglycerides and pancreatitis in patients with familial chy-lomicronaemia syndrome (FCS) in the UK Early Access to Medicines Scheme (EAMS).","volume":"375","author":"Jones","year":"2023","journal-title":"Atherosclerosis"},{"key":"R68-20250729","doi-asserted-by":"crossref","first-page":"2785","DOI":"10.1093\/eurheartj\/ehz209","article-title":"N-acetyl galactosa-mine-conjugated antisense drug to APOC3 mRNA, triglycerides and atherogenic lipoprotein levels.","volume":"40","author":"Alexander","year":"2019","journal-title":"Eur Heart J"},{"key":"R69-20250729","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1093\/eurheartj\/ehab820","article-title":"Apolipoprotein C-III reduction in subjects with moderate hypertriglyceridaemia and at high cardiovascular risk.","volume":"43","author":"Tardif","year":"2022","journal-title":"Eur Heart J"},{"key":"R70-20250729","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1016\/j.jacl.2022.06.005","article-title":"Effect of olezarsen targeting APOC-III on lipoprotein size and particle number measured by NMR in patients with hypertriglyceridemia.","volume":"16","author":"Karwatowska-Prokopczuk","year":"2022","journal-title":"J Clin Lipidol"},{"key":"R71-20250729","doi-asserted-by":"crossref","first-page":"A10357","DOI":"10.1161\/circ.144.suppl_1.10357","article-title":"ARO-APOC3, an investigational RNAi therapeutic, shows similar efficacy and safety in genetically confirmed FCS and non-FCS participants with severe hypertriglyceridemia.","volume":"144","author":"Clifton","year":"2021","journal-title":"Circulation"},{"key":"R72-20250729","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1038\/nm.4390","article-title":"A human APOC3 missense variant and monoclonal antibody accelerate apoC-III clearance and lower triglycer-ide-rich lipoprotein levels.","volume":"23","author":"Khetarpal","year":"2017","journal-title":"Nat Med"},{"key":"R73-20250729","doi-asserted-by":"crossref","first-page":"2054","DOI":"10.1016\/j.jacc.2017.02.030","article-title":"ANGPTL3 deficiency and protection against coronary artery disease.","volume":"69","author":"Stitziel","year":"2017","journal-title":"J Am Coll Cardiol"},{"key":"R74-20250729","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1177\/2047487319884378","article-title":"Angiopoietin-like 3 and subclinical peripheral arterial disease: evidence from the Brisighella Heart Study.","volume":"27","author":"Ruscica","year":"2020","journal-title":"Eur J Prev Cardiol"},{"key":"R75-20250729","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1194\/jlr.M300031-JLR200","article-title":"A decreased expression of angiopoietin-like 3 is protective against atherosclerosis in apoE-deficient mice.","volume":"44","author":"Ando","year":"2003","journal-title":"J Lipid Res"},{"key":"R76-20250729","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1194\/jlr.M054890","article-title":"ANGPTL3 blockade with a human monoclonal antibody reduces plasma lipids in dyslipidemic mice and monkeys.","volume":"56","author":"Gusarova","year":"2015","journal-title":"J Lipid Res"},{"key":"R77-20250729","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1056\/NEJMoa1612790","article-title":"Genetic and pharmacologic inactivation of ANGPTL3 and cardiovascular disease.","volume":"377","author":"Dewey","year":"2017","journal-title":"N Engl J Med"},{"key":"R78-20250729","doi-asserted-by":"crossref","first-page":"5780","DOI":"10.1016\/j.vaccine.2021.08.077","article-title":"A VLP-based vaccine targeting ANGPTL3 lowers plasma triglyc-erides in mice.","volume":"39","author":"Fowler","year":"2021","journal-title":"Vaccine"},{"key":"R79-20250729","doi-asserted-by":"crossref","first-page":"100101","DOI":"10.1016\/j.jlr.2021.100101","article-title":"Antisense oligonucleotide-mediated inhibition of angiopoietin-like protein 3 increases reverse cholesterol transport in mice.","volume":"62","author":"Bell","year":"2021","journal-title":"J Lipid Res"},{"key":"R80-20250729","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1161\/CIRCULATIONAHA.117.031335","article-title":"Reduced blood lipid levels with in vivo CRISPR-Cas9 base editing of ANGPTL3.","volume":"137","author":"Chadwick","year":"2018","journal-title":"Circulation"},{"key":"R81-20250729","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1056\/NEJMoa1701329","article-title":"Cardio-vascular and metabolic effects of ANGPTL3 antisense oligonucleotides.","volume":"377","author":"Graham","year":"2017","journal-title":"N Engl J Med"},{"key":"R82-20250729","doi-asserted-by":"crossref","first-page":"3936","DOI":"10.1093\/eurheartj\/ehaa689","article-title":"Vupanorsen, an N-acetyl galactosamine-conjugated antisense drug to ANGPTL3 mRNA, lowers triglycerides and atherogenic lipoproteins in patients with diabetes, hepatic steatosis, and hypertriglyceridaemia.","volume":"41","author":"Gaudet","year":"2020","journal-title":"Eur Heart J"},{"key":"R83-20250729","doi-asserted-by":"crossref","first-page":"2307","DOI":"10.1056\/NEJMoa2031049","article-title":"Evinacumab in patients with refractory hypercholesterolemia.","volume":"383","author":"Rosenson","year":"2020","journal-title":"N Engl J Med"},{"key":"R84-20250729","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1001\/jamacardio.2023.2921","article-title":"Longer-term efficacy and safety of evinacumab in patients with refractory hypercholesterolemia.","volume":"8","author":"Rosenson","year":"2023","journal-title":"JAMA cardiology"},{"key":"R85-20250729","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa2004215","article-title":"Evinacumab for homozygous familial hypercholesterolemia.","volume":"383","author":"Raal","year":"2020","journal-title":"N Engl J Med"},{"key":"R86-20250729","doi-asserted-by":"crossref","first-page":"2216","DOI":"10.1038\/s41591-023-02494-2","article-title":"RNA interference targeting ANGPTL3 for triglyceride and cholesterol lowering: phase 1 basket trial cohorts.","volume":"29","author":"Watts","year":"2023","journal-title":"Nat Med"}],"container-title":["Coronary Artery Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MCA.0000000000001375","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,29]],"date-time":"2025-07-29T18:03:26Z","timestamp":1753812206000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MCA.0000000000001375"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,29]]},"references-count":86,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.1097\/mca.0000000000001375","relation":{},"ISSN":["0954-6928"],"issn-type":[{"value":"0954-6928","type":"print"}],"subject":[],"published":{"date-parts":[[2024,4,29]]}}}